Hearing loss has long been treated as an unavoidable part of getting older. But in the past decade, researchers and public‑health bodies have begun to treat it instead as a modifiable risk factor for cognitive decline — and new clinical evidence and global guidance are making the case that hearing care belongs in any public effort to protect brain health.
That message is both practical and optimistic. Hearing evaluation and—when appropriate—hearing devices and related support services are widely available, carry little medical risk, and can improve quality of life immediately. Growing trial evidence suggests there may also be measurable benefits for thinking and memory over time, especially in people already at elevated risk of cognitive decline. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10529382/))
What the big trials are saying
ACHIEVE, a large randomized trial led by researchers at Johns Hopkins and published in Lancet, tested whether providing hearing care (counselling plus hearing aids) to older adults with untreated hearing loss would slow cognitive decline. In the combined trial population, the study found no statistically significant difference in three‑year cognitive change between the hearing‑intervention group and a health‑education control. But a prespecified sensitivity analysis showed that the hearing intervention did reduce cognitive decline in the subgroup of participants who were at higher baseline risk for dementia — a promising signal that targeted programs could move the needle. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10529382/))
More recently, the CHOICE randomized clinical trial (published online in JAMA Neurology) examined hearing‑aid treatment in older adults who already had mild cognitive impairment. The trial reported no statistically significant reduction in conversion from mild cognitive impairment to dementia over 24 months — its primary outcome — but did find that people who received the hearing intervention were more likely to show clinically meaningful cognitive improvement on secondary measures. The trial’s authors and independent reviewers interpret these mixed results as evidence that hearing care can have real benefits for some people while also underscoring the need to refine which patients benefit most and when. ([jamanetwork.com](https://jamanetwork.com/journals/jamaneurology/fullarticle/2854483?guestAccessKey=f0cbf253-a98d-4d22-af11-cc118f80be46))
Why the evidence looks mixed — and why that’s still hopeful
At first glance the findings seem contradictory: one trial finds a subgroup benefit, another finds no reduction in dementia incidence but some secondary cognitive gains. Experts point out several reasons the results can differ without negating the broader promise of hearing care.
- Different study populations. ACHIEVE enrolled cognitively healthy older adults aged about 71–85; CHOICE enrolled people with existing mild cognitive impairment. Timing matters: interventions begun earlier in the path to dementia may have different effects than those begun after cognitive impairment is already present. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10529382/))
- Variation in risk. ACHIEVE found that people with a higher burden of dementia risk factors gained the most cognitive benefit from hearing care — suggesting programs targeted to those at higher risk could be especially effective. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10529382/))
- Different outcomes and follow‑up length. Trials measure cognition in multiple ways (global tests, rates of conversion to dementia, domain scores) and follow participants for different lengths of time; some benefits may show up first in day‑to‑day function or in specific cognitive domains rather than as an immediate change in dementia incidence. ([jamanetwork.com](https://jamanetwork.com/journals/jamaneurology/fullarticle/2854483?guestAccessKey=f0cbf253-a98d-4d22-af11-cc118f80be46))
An alignment with major health guidance
Those trial results now sit alongside a major policy shift. In July 2026 the World Health Organization published the second edition of its guidelines on risk reduction for cognitive decline and dementia, which updates recommendations across lifestyle, clinical and environmental domains and supports integrating targeted hearing services as part of dementia risk‑reduction strategies. The WHO document frames hearing care as a public‑health priority because it is common, treatable, and connected to social engagement and other risk factors for cognitive decline. ([who.int](https://www.who.int/publications/i/item/9789240123557%E2%81%A0))
How hearing loss may affect the brain
Researchers describe several plausible pathways linking hearing loss and cognitive decline. Hearing impairment can increase cognitive load (making listening more mentally taxing), reduce social engagement (a known dementia risk factor), and be associated with structural brain changes over time. Genetic and reverse‑causation explanations are also under study — in some cases, brain changes linked to neurodegeneration may themselves affect central auditory processing. That complexity helps explain why treating hearing loss is not portrayed as a cure but as a promising, low‑risk strategy that can be part of broader prevention efforts. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12953099/))
What this means for people and communities
For individuals, the simplest takeaway is practical: if you have trouble hearing, a clinical hearing evaluation is a reasonable step. Even when the primary goal is clearer communication and quality of life, hearing evaluation and access to appropriately fitted devices and counselling may also offer cognitive benefits for many people. Trials suggest the greatest payoff may come when hearing loss is addressed as part of a broader approach to brain health that includes management of vascular risk factors, social engagement and physical activity. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10529382/))
For health systems and policy makers, the evidence points to choices that can expand access — earlier screening, insurance coverage or subsidies for hearing services, and programs that combine hearing care with other risk‑reduction services for older adults. Those investments are relatively low risk and could have outsized benefits if targeted to people at higher dementia risk. ([who.int](https://www.who.int/publications/i/item/9789240123557%E2%81%A0))
The next steps for research and practice
Researchers say more trials are needed that test who benefits most, when to intervene, and how hearing care can be combined with other interventions. In the meantime, clinicians and public‑health leaders can act on current evidence: increase screening, make hearing evaluation easier to obtain, and place hearing care inside comprehensive programs to support healthy aging. The message is hopeful and concrete: treating hearing loss is a practical lever we already have, and the growing body of human trials and global guidance suggests it deserves a central place in efforts to protect the aging brain. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10529382/))
